This early-stage study tests a new radioactive imaging agent called [89Zr]DFO-YS5 to see if it can safely and accurately detect multiple myeloma cells that have a specific protein (CD46). About 20 adults with confirmed multiple myeloma will receive the agent and undergo PET scans…
Phase: PHASE1 • Sponsor: Robert Flavell, MD, PhD • Aim: Diagnosis
Last updated May 17, 2026 04:13 UTC